DONGIOVANNI, PAOLA
DONGIOVANNI, PAOLA
DIPARTIMENTO DI MEDICINA INTERNA (attivo dal 01/01/1998 al 27/04/2012)
Recent advances of drugs monitoring in oral fluid and comparison with blood
2023 S. Casati, M. Binda, P. Dongiovanni, M. Meroni, A. D'Amato, G. Roda, M. Orioli, M. DEL FABBRO, G.M. Tartaglia
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women
2023 A. Cherubini, M. Ostadreza, O. Jamialahmadi, S. Pelusi, E. Rrapaj, E. Casirati, G. Passignani, M. Norouziesfahani, E. Sinopoli, G. Baselli, C. Meda, P. Dongiovanni, D. Dondossola, N. Youngson, A. Tourna, S. Chokshi, E. Bugianesi, E. Study Investigators, S. DELLA TORRE, D. Prati, S. Romeo, L. Valenti
Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis
2023 J. Kang, J. Postigo-Fernandez, K. Kim, C. Zhu, J. Yu, M. Meroni, B. Mayfield, A. Bartolomé, D.H. Dapito, A.W. Ferrante, P. Dongiovanni, L. Valenti, R.J. Creusot, U.B. Pajvani
Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH
2023 M.P. Moore, X. Wang, H. Shi, M. Meroni, A. Cherubini, L. Ronzoni, E.J. Parks, J.A. Ibdah, R.S. Rector, L. Valenti, P. Dongiovanni, I. Tabas
Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation
2023 P. Dongiovanni, M. Meroni, S. Casati, R. Goldoni, D.V. Thomaz, N.S. Kehr, D. Galimberti, M. Del Fabbro, G.M. Tartaglia
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
2023 R.M. Pipitone, F. Malvestiti, G. Pennisi, O. Jamialahmadi, P. Dongiovanni, G. Bertolazzi, J. Pihlajamäki, H. Yki-Järvinen, U. Vespasiani-Gentilucci, F. Tavaglione, S. Maurotti, C. Bianco, G. Di Maria, M. Enea, A.L. Fracanzani, V. Kärjä, G. Lupo, V. Männistö, M. Meroni, R. Piciotti, S. Qadri, R. Zito, A. Craxì, V. Di Marco, C. Cammà, C. Tripodo, L. Valenti, S. Romeo, S. Petta, S. Grimaudo
Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
2022 A. Cespiati, M. Meroni, R. Lombardi, G. Oberti, P. Dongiovanni, A.L. Fracanzani
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
2022 M. Longo, M. Meroni, E. Paolini, V. Erconi, F. Carli, F.R. Fortunato, D. Ronchi, R. Piciotti, S. Sabatini, C. Macchi, A. Alisi, L. Miele, G. Soardo, G.P. Comi, L.V.C. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P. Dongiovanni
Rare ATG7 genetic variants predispose patients to severe fatty liver disease
2022 G.A. Baselli, O. Jamialahmadi, S. Pelusi, E. Ciociola, F. Malvestiti, M. Saracino, L. Santoro, A. Cherubini, P. Dongiovanni, M. Maggioni, C. Bianco, F. Tavaglione, A. Cespiati, R.M. Mancina, R. D'Ambrosio, V. Vaira, S. Petta, L. Miele, U. Vespasiani-Gentilucci, A. Federico, J. Pihlajamaki, E. Bugianesi, A.L. Fracanzani, H.L. Reeves, G. Soardo, D. Prati, S. Romeo, L.V. Valenti
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni
{PD}-1/{PD}-L1 Immuno-Mediated Therapy in {NAFLD}: Advantages and Obstacles in the Treatment of Advanced Disease
2022 R. Lombardi, R. Piciotti, P. Dongiovanni, M. Meroni, S.R. Fargion, A.L. Fracanzani
Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
2022 M. Meroni, M. Longo, E. Paolini, G. Tria, M. Ripolone, L. Napoli, M. Moggio, A.L. Fracanzani, P. Dongiovanni
Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown
2022 F. Cinque, A. Cespiati, R. Lombardi, A. Costantino, G. Maffi, F. Alletto, L. Colavolpe, P. Francione, G. Oberti, E. Fatta, C. Bertelli, G. Sigon, P. Dongiovanni, M. Vecchi, S. Fargion, A.L. Fracanzani
The α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. DI PIERRO, P. Dongiovanni
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
2021 N. Panera, M. Meroni, M. Longo, A. Crudele, L. Valenti, E. Bellacchio, L. Miele, V. D'Oria, E. Paolini, M. Maggioni, A.L. Fracanzani, A. Alisi, P. Dongiovanni
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease
2021 S. Grimaudo, P. Dongiovanni, J. Pihlajamaki, M. Eslam, H. Yki-Jarvinen, R.M. Pipitone, G. Baselli, C. Camma, V. Di Marco, M. Enea, M. Longo, G. Pennisi, D. Prati, R. Zito, A.L. Fracanzani, A. Craxi, J. George, S. Romeo, L. Valenti, S. Petta
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?
2021 M. Longo, M. Meroni, E. Paolini, C. Macchi, P. Dongiovanni
Genetics, immunity and nutrition boost the switching from nash to hcc
2021 P. Dongiovanni, M. Meroni, M. Longo, S. Fargion, A.L. Fracanzani
Genetics is of the essence to face NAFLD
2021 M. Meroni, M. Longo, G. Tria, P. Dongiovanni
$\upalpha$-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study [alpha-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study]
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. Di Pierro, P. Dongiovanni